Evidence map›Paper›PMID 40072815›Full record

Observational studyJapanese journal of ophthalmology2025

Comparison of intraocular pressure changes in Japanese patients with neovascular age-related macular degeneration treated with aflibercept or faricimab.

Junichiro Honjo, Ryo Mukai, Kanako Itagaki, Keiichiro Tanaka, Koki Norikawa, Yutaka Kato, Akihito Kasai, Yukinori Sugano, Tetsuju Sekiryu

Abstract readObservational StudyComparative Study
PubMed Publisher
In one paragraph

Observational study in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Junichiro HonjoDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Ryo MukaiDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Kanako ItagakiDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Keiichiro TanakaDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Koki NorikawaDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Yutaka KatoDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Akihito KasaiDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Yukinori SuganoDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan.
Tetsuju SekiryuDepartment of Ophthalmology, Fukushima Medical University, Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan. sekiryu@fmu.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the short-term changes in intraocular pressure (IOP) following intravitreal injections of aflibercept or faricimab in Japanese patients with neovascular age-related macular degeneration (nAMD). STUDY

designRetrospective observational study.

methodsThis retrospective observational study included 161 eyes from 160 Japanese patients diagnosed with nAMD. Of these, 127 eyes (127 patients) were treated with 2 mg/0.05 mL aflibercept, and 34 eyes (33 patients) received 6 mg/0.05 mL faricimab. Each group underwent three consecutive monthly injections. The IOP in each treated eye was measured using non-contact tonometry at each visit over a 3-month period following the initial injection.

resultsThe mean baseline IOP in the aflibercept group was 14.4 ± 2.8 mmHg, decreasing to 13.2 ± 3.0 mmHg after 3 months (P < 0.001), whereas the mean baseline IOP in the faricimab group was 13.8 ± 2.1 mmHg, with a change to 13.5 ± 1.5 mmHg after 3 months (P = 0.1873).

conclusionThe loading phase treatment with aflibercept resulted in a decrease in IOP. Faricimab showed a similar trend, there was no significant difference between the two treatments.

Indexed as

Intraocular PressureReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, BispecificDose-Response Relationship, DrugEast Asian PeopleFemaleFluorescein AngiographyFollow-Up StudiesHumansIntravitreal InjectionsJapanafliberceptAngiogenesis InhibitorsAntibodies, BispecificfaricimabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAfliberceptAnti-vascular endothelial growth factorFaricimabIntraocular pressureNeovascular age-related macular degeneration

Identifiers

PMID40072815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.